Will Intercept’s New NASH Analysis Pass FDA’s Muster?
Consensus Method Shows Consistent Efficacy
The new analysis of REGENERATE, based on an FDA-requested methodology, shows continued efficacy for OCA, but analysts were circumspect about whether the benefit/risk profile would sway the agency.
